FLT4 (18th by MUFFINN yet below 4000th by all three gene-centric methods in LAML samples), ATR (28th by MUFFINN yet below 10,000th by all three gene-centric methods in BRCA samples) and MAP2K2 (fifth by MUFFINN yet below 11,000th by all three gene-centric methods in papillary thyroid carcinoma (THCA) samples) were recently added to the updated CGC gene list. This evidence concerns the gene FLT4 and differentiated thyroid carcinoma.